Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | ADA | P00813 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15257614 | 0.89 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BIMPDH2IMPDH1 | |
| SCHEMBL15257714 | 0.89 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BIMPDH2IMPDH1 | |
| SCHEMBL15045902 | 0.89 | ADORA2A (0.52) | ADORA2ANT5EADORA3ADA | |
| SCHEMBL17232110 | 0.89 | NT5E (0.43) | ADORA2AIMPDH2IMPDH1NT5EADORA3 | |
| SCHEMBL15259226 | 0.89 | ADORA2A (0.52) | ADORA2ANT5EADORA3ADA | |
| SCHEMBL15459915 | 0.89 | ADORA2A (0.60) | ADORA2AADORA1ADORA2BADORA3ADA | |
| SCHEMBL14583683 | 0.89 | ADORA2A (0.60) | ADORA2AADORA1ADORA2BADORA3ADA | |
| SCHEMBL13559229 | 0.89 | ADORA2A (0.60) | ADORA2AADORA1ADORA2BADORA3ADA | |
| SCHEMBL15045893 | 0.84 | ADORA2A (0.52) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL15044551 | 0.83 | ADORA2A (0.45) | ADORA2AADORA1ADORA2BIMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624249-B2 | Nucleoside kinase bypass compositions and methods | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | DCK, DTYMK, TK1 | ADORA2A 353/4885ADORA1 1092/4885ADORA2B 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.